M
MedAlliance
Developing ground-breaking technology for the treatment of coronary and peripheral artery disease
About MedAlliance
Established in 2008 by Jeffrey B. Jump, MedAlliance SA is a Swiss-based medical technology company focused on developing and commercializing drug-device combination products for treating coronary and peripheral artery disease. Mr. Jump, who serves as Chairman and CEO, leveraged his extensive experience in the medical device industry, including a 13-year tenure as CEO of Biosensors International, to identify shortcomings in existing stent technologies. This insight led to the company's mission: to create a treatment that delivers a therapeutic drug without leaving a permanent metal implant behind.
The company's core product is the SELUTION SLR™ (Sustained Limus Release), a drug-eluting balloon (DEB). This device addresses atherosclerosis, the hardening of arteries, by delivering the anti-restenotic drug sirolimus to the affected vessel during an angioplasty procedure. Its technology features unique MicroReservoirs—a blend of biodegradable polymer and sirolimus—that coat the balloon. When the balloon is inflated within the artery, the proprietary Cell Adherent Technology (CAT™) ensures the MicroReservoirs adhere to the vessel wall, providing a controlled and sustained drug release for up to 90 days. This approach is designed to prevent restenosis, or the re-narrowing of the artery, a common complication with permanent metal stents.
MedAlliance primarily serves interventional cardiologists and vascular surgeons in hospitals and clinics worldwide. The company achieved significant regulatory milestones, including CE Mark approvals in 2020 for both peripheral and coronary artery disease treatment. It also became the first DEB company to receive multiple 'Breakthrough Device Designations' and Investigational Device Exemption (IDE) approvals from the U.S. FDA for various indications, including in-stent restenosis and below-the-knee lesions. In October 2023, the company's trajectory culminated in a landmark acquisition by Cordis, a global leader in interventional vascular technology. The deal, valued at up to $1.135 billion, involved an upfront payment and future milestone-based payments, reflecting the significant market potential of the SELUTION SLR™ technology. The acquisition provides MedAlliance with Cordis's extensive global sales and distribution network, aiming to accelerate the worldwide adoption of its stent-less angioplasty solution.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 61
- Open positions
- None listed
- Dealroom signal
- 61.5/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Cardiology and cardiovascular, Tech for Hospitals and Clinics, DT and LS, science-based
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Feb 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2022 | $200M | $325M | Cordis | ↗ |
| GROWTH EQUITY VCOther financing | Mar 2021 | $50M | — | CITIC Capital | — |
Growth signals
Latest recorded traffic for MedAlliance is 200 monthly website visits, down 33.3% over the last three months. MedAlliance's team declined 22.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
MedAlliance in the Nyon ecosystem
The MedAlliance office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
CITIC Capital
Other known investors1 additional known investor
Cordis
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MedAlliance on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MedAlliance’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










